TEVA Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- 13.57
- PEG ratio
- 0.80
- P/B
- 4.61
- P/S (TTM)
- 2.19
- EV/EBITDA
- 15.68
Profitability & growth
- ROE (TTM)
- 21.6%
- Operating margin
- 19.2%
- Revenue growth YoY
- 2.3%
- Dividend yield
- —
- Beta
- 0.85
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Teva Pharma Industries Ltd ADR
Company profileTeva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Classification
- Sector
- Healthcare
- Exchange
- NYSE
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 124 DVORA HANEVI?A ST., TEL AVIV-YAFO, ISRAEL
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer